Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Astellas Teams With Proteostasis
by Lisa M. Jarvis
November 10, 2014
| A version of this story appeared in
Volume 92, Issue 45
Astellas has teamed with Cambridge, Mass.-based biotech firm Proteostasis Therapeutics to develop drugs that modulate the body’s response to stress caused by an accumulation of unfolded proteins inside cells. The companies will jointly develop compounds against an undisclosed genetic disease but could expand their pact to explore other indications. Astellas will shell out an undisclosed up-front fee and research funding. If a drug reaches the market, Proteostasis could see overall payments exceeding $400 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter